» Articles » PMID: 27919182

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology

Abstract

Objective: Research and clinical translation in schizophrenia is limited by inconsistent definitions of treatment resistance and response. To address this issue, the authors evaluated current approaches and then developed consensus criteria and guidelines.

Method: A systematic review of randomized antipsychotic clinical trials in treatment-resistant schizophrenia was performed, and definitions of treatment resistance were extracted. Subsequently, consensus operationalized criteria were developed through 1) a multiphase, mixed methods approach, 2) identification of key criteria via an online survey, and 3) meetings to achieve consensus.

Results: Of 2,808 studies identified, 42 met inclusion criteria. Of these, 21 studies (50%) did not provide operationalized criteria. In the remaining studies, criteria varied considerably, particularly regarding symptom severity, prior treatment duration, and antipsychotic dosage thresholds; only two studies (5%) utilized the same criteria. The consensus group identified minimum and optimal criteria, employing the following principles: 1) current symptoms of a minimum duration and severity determined by a standardized rating scale; 2) moderate or worse functional impairment; 3) prior treatment consisting of at least two different antipsychotic trials, each for a minimum duration and dosage; 4) systematic monitoring of adherence and meeting of minimum adherence criteria; 5) ideally at least one prospective treatment trial; and 6) criteria that clearly separate responsive from treatment-resistant patients.

Conclusions: There is considerable variation in current approaches to defining treatment resistance in schizophrenia. The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation.

Citing Articles

A Review of Clinical Advances and Challenges in Clozapine-Induced Myocarditis.

Li M, Bai Y, Wang Y, Xing H, Zhang Y, Ding W Neuropsychiatr Dis Treat. 2025; 21:525-538.

PMID: 40070369 PMC: 11895683. DOI: 10.2147/NDT.S502312.


Along-tract white matter abnormalities and their clinical associations in recent-onset and chronic schizophrenia.

Joo S, Park H, Park J, Lee J Schizophrenia (Heidelb). 2025; 11(1):37.

PMID: 40050653 PMC: 11885433. DOI: 10.1038/s41537-025-00586-1.


Network analysis of clinical features in patients with treatment-resistant schizophrenia.

Li W, Zhao J, Hu N, Zhang W Front Psychiatry. 2025; 16:1537418.

PMID: 39980982 PMC: 11839625. DOI: 10.3389/fpsyt.2025.1537418.


Theoretical Potential of Hericium Erinaceus Supplementation as an Add-On to Antipsychotics in Chronic and Treatment-Resistant Schizophrenia.

Baker J, Newman S Psychopharmacol Bull. 2025; 55(2):41-59.

PMID: 39935672 PMC: 11809503.


Investigating DRD2 and HTR2A polymorphisms in treatment-resistant schizophrenia: a comparative analysis with other treatment-resistant mental disorders and the healthy state.

Del Casale A, Gentile G, Lardani S, Modesti M, Arena J, Zocchi C Eur Arch Psychiatry Clin Neurosci. 2025; .

PMID: 39934320 DOI: 10.1007/s00406-025-01970-9.


References
1.
Agid O, Arenovich T, Sajeev G, Zipursky R, Kapur S, Foussias G . An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011; 72(11):1439-44. DOI: 10.4088/JCP.09m05785yel. View

2.
Frogley C, Taylor D, Dickens G, Picchioni M . A systematic review of the evidence of clozapine's anti-aggressive effects. Int J Neuropsychopharmacol. 2012; 15(9):1351-71. DOI: 10.1017/S146114571100201X. View

3.
Velligan D, Wang M, Diamond P, Glahn D, Castillo D, Bendle S . Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007; 58(9):1187-92. DOI: 10.1176/ps.2007.58.9.1187. View

4.
Conley R, Carpenter Jr W, Tamminga C . Time to clozapine response in a standardized trial. Am J Psychiatry. 1997; 154(9):1243-7. DOI: 10.1176/ajp.154.9.1243. View

5.
Remington G, Agid O, Foussias G, Ferguson L, McDonald K, Powell V . Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?. Psychopharmacology (Berl). 2012; 225(3):505-18. DOI: 10.1007/s00213-012-2922-7. View